By Thomas Anderson and Rotem Petranker — 2018
There is a growing research literature suggesting psychedelics hold incredible promise for treating mental health ailments ranging from depression and anxiety to PTSD. But how do we know for sure?
Read on theconversation.com
CLEAR ALL
The Food and Drug Administration (FDA) has approved the design of two Phase 3 clinical trials of MDMA for treating PTSD, according to the Multidisciplinary Association for Psychedelic Studies (MAPS), which is funding and leading the clinical trials.
1
The world’s leading advocate for the medicinal use of psychedelics on the ghost of Timothy Leary, why Ecstasy could cure PTSD, and the best place to trip in Boston.
Psychedelic drugs—once promising research subjects that were decades ago relegated to illicit experimentation in dorm rooms—have been steadily making their way back into the lab for a revamped 21st-century-style look.
My first psilocybin journey began around an altar in the middle of a second-story loft in a suburb of a small city on the Eastern Seaboard.
2
Roland Griffiths' psilocybin experiments have produced striking evidence for therapeutic uses of hallucinogens.
A new generation of research into psilocybin could change how we treat numerous mental health conditions.
Scientists Roland Griffiths and Matthew Johnson sit down with journalist Anderson Cooper to discuss the promise of psychedelics as a form of treatment for anxiety, depression, addiction, and more.
Roland Griffiths is a Johns Hopkins University professor, researcher and expert in the field of pharmacology. He is best known for his research into the beneficial effects psilocybin on cancer patients.
The scientist talks to Laurence Phelan about fighting the establishment, battling preconceptions and breaking down egos.
In a recent UK trial, 12 patients with major depression took a pill quite different to commonly prescribed antidepressants: 25mg of psilocybin, the psychedelic compound found in magic mushrooms.